OneSource Specialty Pharma's Bengaluru Facility Receives USFDA EIR with VAI Classification
NiveshIQ
NSE: ONESOURCE · Healthcare
Onesource Specialty Pharma Ltd.
₹1,558.20▼ ₹4.80 (-0.31%)
Price Chart · Daily closes
1Y
6M
3M
1M
1W
1D
⚡ Intelligence Signals
5 active
🟢 Bullish Earnings Catalyst
📊 RS Laggard (5D)
🔄 Sector Sweep
⚡ Signals Aligned
📉 Pullback
NiveshIQ has detected 5 active signals on ONESOURCE. Sign up free to see what each signal means and how it affects the stock.
Unlock signals — freeExpected Move
1D / 1W / 1M range derived from news, fundamentals & technicals
1 Day
±1.8%
1 Week
±4.2%
1 Month
±9.6%
Confidence Score
Based on historical directional & magnitude accuracy for this stock
74
/ 100
About Onesource Specialty Pharma Ltd.
OneSource Specialty Pharma Limited (formerly Stelis Biopharma) is a biopharmaceutical firm that designs, develops, manufactures, and commercialises biologic drug products across India, Singapore, the United States, Spain and other international markets. The company offers end‑to‑end CDMO services for pre‑clinical, clinical and commercial stages, and supplies drug‑device solutions such as prefilled syringes, autoinjectors, and sterile injectables. Its product portfolio spans recombinant proteins, monoclonal antibodies, biosimilars, cell and gene therapies, and RNA therapeutics. In FY2023 the company generated ₹1,543 crore in revenue but reported a net loss of ₹49 crore, reflecting investment in R&D and capacity expansion. Recent developments include a 10‑year licensing agreement with Avalon
Financial Highlights
| Metric | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹172.00 Cr +341.00% | ₹1,445 Cr +740.10% | ₹1,422 Cr -1.61% |
| EBITDA Margin | -31.90% | 32.29% | 21.40% |
| Net Profit | -95.10% | ||
| EPS | – | ₹-1.63 | ₹-6.44 |
Annual figures in Indian Rupees (Crores). Source: company filings (NSE).
Recent News
OneSource Receives USFDA EIR with VAI Classification, Marking Completion of Inspection Process at its Sterile Product Division (SPD) Facility in Bengaluru
OneSource Specialty Pharma gets USFDA VAI for Bengaluru sterile facility
🔒
+ 3 more stories about Onesource Specialty Pharma Ltd.
Full news feed with AI impact summaries, synced in real time.
Sign up free — it's instantStrategic Outlook
- Q2FY27 results: revenue ₹965 Cr, PAT ₹82 Cr, EPS ₹7.19, EBITDA margin 29.7%. Growth context: revenue YoY +156.9%, PAT YoY +686.7%, revenue QoQ +115.0%, PAT QoQ +230.0%.
Management commentary points to product launches, approvals, and therapy-mix improvement and new capacity addition and c...
FY26 (last completed FY): revenue ₹1, 422 Cr, PAT ₹-74 Cr, EBITDA margin 21.4%, EPS ₹-6.44. Year-on-year: revenue YoY -1...
🔒
+ 3 more outlook points
Growth drivers, key risks, and upcoming catalysts — unlocked free.
Sign up free — it's instantMore Healthcare stocks
Everything you unlock with a free account
⚡Intelligence Signals — AI-detected patterns across news, earnings & technicals
📈Price Chart — 1D to 1Y daily closes for ONESOURCE
🎯Expected Move — 1D / 1W / 1M range from news, fundamentals & technicals
🧠Confidence Score — Historical directional & magnitude accuracy for this stock
🎙Analyst Target Price — Consensus target with buy / hold / sell breakdown
📰Full News Feed — All stories synced in real time with AI impact summaries
🔭Strategic Outlook — Growth drivers, risks & upcoming catalysts
📊Watchlist & Portfolio — Track ONESOURCE alongside your other holdings
Unlock full ONESOURCE research — free
No credit card · No trial · Always free to start
Frequently Asked Questions
What AI signals does NiveshIQ provide for Onesource Specialty Pharma Ltd.?
NiveshIQ detects active intelligence signals for Onesource Specialty Pharma Ltd. (ONESOURCE) — including earnings catalysts, relative strength patterns, sector sweeps, and pullback setups. It also shows an Expected Move (1D/1W/1M range based on news, fundamentals and technicals) and a Confidence Score based on historical directional and magnitude accuracy. These are exclusive to NiveshIQ.
What are the key financials for Onesource Specialty Pharma Ltd.?
Onesource Specialty Pharma Ltd. operates in the Healthcare sector with a market capitalisation of ₹2,118,596.2L Cr. Revenue, net profit, EPS and EBITDA margins across the last three annual periods are shown above, sourced from BSE filings.
Does NiveshIQ provide investment advice?
No. NiveshIQ provides educational market intelligence and research context, not investment advice or buy/sell recommendations.